KYMR

Several events impacted Kymera Therapeutics' stock in the past six months. Fourth Quarter and Full Year 2025 Financial Results were reported on February 26, 2026, and First Quarter 2026 Financial Results were announced on April 30, 2026, both providing pipeline and partnership updates. Positive results from the KT-621 Phase 1b Atopic Dermatitis Trial were presented at the AAD Annual Meeting in March 2026. The FDA granted Fast Track designation to KT-621 for eosinophilic asthma in April 2026. Dosing began in the KT-579 Phase 1 trial in February 2026, with data expected in the second half of 2026. Gilead exercised its option on KT-200 in April 2026, triggering a $45 million milestone payment. Sanofi ended work on KT-474 but prioritized KT-485. Kymera's stock increased by 10.6% between the beginning of 2026 and May 9, 2026, and by 289.96% over the last 12 months.